EXHIBIT 2.2
STOCKHOLDER SUPPORT AGREEMENT
THIS STOCKHOLDER SUPPORT AGREEMENT (this “Agreement”) is entered into as of January 28, 2020, by and among Conatus Pharmaceuticals Inc., a Delaware corporation (“Parent”), Histogen Inc., a Delaware corporation (the “Company”), and the undersigned stockholders of Parent (collectively, solely in each stockholder’s capacity as a stockholder of the Company, the “Stockholders”).
WHEREAS, as of the date hereof, each Stockholder is the sole record and beneficial owner of and has the sole power to vote (or to direct the voting of) the number of shares of Company common stock, par value $0.0001 per share (such stock, the “Common Stock”, and such shares, the “Shares”), set forth on such Stockholder’s signature page hereto (such Shares, the “Original Shares”);
WHEREAS, Parent, the Company and Chinook Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), are concurrently entering into an Agreement and Plan of Merger and Reorganization, dated on or about the date hereof (as amended from time to time in accordance with the terms thereof, the “Merger Agreement”), attached hereto asExhibit A, pursuant to which Merger Sub shall be merged with and into the Company, with the Company continuing as the surviving corporation thereafter (the “Merger”);
WHEREAS, in connection with the Merger, the Merger Agreement contemplates that Parent will (a) to the extent required by Nasdaq Marketplace Rule 5110, prepare and file (or, at the Company’s request, assist the Company in preparing and filing) an initial listing application for the Common Stock on The Nasdaq Stock Market LLC (the “Nasdaq Listing Application”), (b) amend its certificate of incorporation, with the approval of its stockholders, to effect a reverse stock split of all outstanding shares of Common Stock at a reverse stock split ratio mutually agreed to by the Company and Parent, in such combination ratio as may be reasonably necessary to obtain approval of the Nasdaq Listing Application (the “Parent Reverse Stock Split”), without reducing the number of authorized shares of Parent Common Stock after the effectiveness thereof except to the extent mutually agreed by the Parties, and (c) obtain the approval of its stockholders to approve Parent’s 2020 Incentive Award Plan, in a form approved by the Company and Parent (such Parent approval not to be unreasonably withheld, delayed or conditioned), as further described in the Merger Agreement (the “2020 Incentive Plan”);
WHEREAS, (a) the affirmative vote of the holders of a majority of the outstanding shares of Common Stock is the only vote of the holders of any class or series of Parent’s capital stock necessary to approve the Parent Reverse Stock Split, and (b) the affirmative vote of a majority of the votes cast at a meeting of the Parent stockholders is the only vote of the holders of any class or series of Parent’s capital stock necessary to approve and adopt the Merger Agreement and the Merger and other transactions contemplated thereby (the “Contemplated Transactions”), including the issuance of the shares of Common Stock to the stockholders of the Company pursuant to the terms of the Merger Agreement, and all other Parent Stockholder Matters (as defined below) (the “Required Parent Stockholder Vote”);
-1-